Novartis, Par Settle Patent Suit Over Lotrel

Law360 (February 12, 2009, 12:00 AM EST) -- Novartis International AG and Par Pharmaceutical Cos. Inc. have moved to dismiss a patent suit over Par's proposed generic version of Novartis' billion-dollar hypertension drug Lotrel.

On Wednesday, Judge Harold A. Ackerman of the U.S. District Court for the District of New Jersey signed off on a stipulation of dismissal the two companies filed last week.

The stipulation does not indicate whether there was a settlement in the case, and representatives for both Novartis and Par could not be reached for comment.

The case began in...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.